Daidzein modulates cocaine-reinforcing effects and cue-induced cocaine reinstatement in CD-1 male mice.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 02 10 2020
accepted: 08 03 2021
pubmed: 12 4 2021
medline: 6 7 2021
entrez: 11 4 2021
Statut: ppublish

Résumé

Cocaine addiction is a chronic relapsing disorder that lacks of an effective treatment. Isoflavones are a family of compounds present in different plants and vegetables like soybeans that share a common chemical structure. Previous studies have described that synthetic derivatives from the natural isoflavone daidzin can modulate cocaine addiction, by a mechanism suggested to involve aldehyde-dehydrogenase (ALDH) activities. Based on these previous studies, we investigated the effects of three natural isoflavones, daidzin, daidzein, and genistein, on the modulation of the cocaine reinforcing effects and on cue-induced reinstatement in an operant mouse model of cocaine self-administration. Chronic treatment with daidzein or genistein decreased operant responding to obtain cocaine intravenous infusions. On the other hand, daidzein and daidzin, but not genistein, were effective in decreasing cue-induced cocaine reinstatement. Complementary studies revealed that daidzein effects on cocaine reinforcement were mediated through a mechanism that involved dopamine type-2/3 receptors (DA-D2/3) activities. Our results suggest that these natural compounds alone or in combination can be a potential therapeutic approach for cocaine addiction. Further clinical studies are required in order to ascertain their potential therapeutic use.

Identifiants

pubmed: 33839903
doi: 10.1007/s00213-021-05820-z
pii: 10.1007/s00213-021-05820-z
pmc: PMC8233246
doi:

Substances chimiques

Dopamine Uptake Inhibitors 0
Isoflavones 0
Phytoestrogens 0
daidzein 6287WC5J2L
Cocaine I5Y540LHVR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1923-1936

Subventions

Organisme : Instituto de Salud Carlos III
ID : RD16/0017/0020
Organisme : Instituto de Salud Carlos III
ID : RD16/0017/003
Organisme : Instituto de Salud Carlos III
ID : CIBEROBN
Organisme : Ministerio de Ciencia Tecnología y Telecomunicaciones
ID : EC10-166
Organisme : Departament de Salut, Generalitat de Catalunya
ID : 2017 SGR 669
Organisme : Departament de Salut, Generalitat de Catalunya
ID : TECCIT2014
Organisme : Departament de Salut, Generalitat de Catalunya
ID : 2015-NeuroPhar
Organisme : Departament de Salut, Generalitat de Catalunya
ID : #2017-SRG-316
Organisme : Departament de Salut, Generalitat de Catalunya
ID : 2017-SGR-138
Organisme : Departament de Salut, Generalitat de Catalunya
ID : 2015-BAPP

Références

Nat Neurosci. 2013 Apr;16(4):383-5
pubmed: 23416448
Nutr Rev. 2003 Jan;61(1):1-33
pubmed: 12638461
Behav Pharmacol. 2014 Apr;25(2):147-57
pubmed: 24603339
Carcinogenesis. 1996 Feb;17(2):271-5
pubmed: 8625449
Acta Psychiatr Scand Suppl. 1992;369:15-26
pubmed: 1471547
Biom J. 2008 Jun;50(3):346-63
pubmed: 18481363
Br J Pharmacol. 2019 Nov;176(21):4159-4172
pubmed: 30874305
N Engl J Med. 2003 Sep 4;349(10):975-86
pubmed: 12954747
Psychopharmacology (Berl). 2015 May;232(10):1767-78
pubmed: 25420611
Mol Interv. 2009 Aug;9(4):175-87
pubmed: 19720750
J Subst Abuse Treat. 2001 Oct;21(3):111-7
pubmed: 11728784
Alcohol Clin Exp Res. 2009 Nov;33(11):1935-44
pubmed: 19673742
J Med Food. 2006 Spring;9(1):1-10
pubmed: 16579721
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10008-12
pubmed: 8234248
Int J Neuropsychopharmacol. 2018 Apr 1;21(4):382-392
pubmed: 29294029
Neuropsychopharmacology. 2007 Jul;32(7):1433-51
pubmed: 17164822
Horm Behav. 2014 Feb;65(2):77-87
pubmed: 24355096
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007024
pubmed: 20091613
Neuropsychopharmacology. 2010 Nov;35(12):2440-9
pubmed: 20736996
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2198-203
pubmed: 9482862
Curr Med Chem. 2017;24(4):365-375
pubmed: 27804870
Psychopharmacology (Berl). 2005 Nov;183(1):72-80
pubmed: 16163519
J Neurochem. 1995 Nov;65(5):2096-104
pubmed: 7595495
EXS. 1994;71:371-81
pubmed: 8032168
Drug Alcohol Depend. 2016 Mar 1;160:135-42
pubmed: 26817621
Nutr Rev. 2013 Aug;71(8):562-72
pubmed: 23865800
Lancet. 1948 Dec 25;2(6539):1001-4
pubmed: 18103475
Synapse. 1999 Dec;34(3):222-7
pubmed: 10523759
Psychopharmacology (Berl). 2006 Jan;184(2):212-20
pubmed: 16362403
J Neurosci. 2016 Jul 27;36(30):7807-16
pubmed: 27466327
Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8
pubmed: 16503828
Psychopharmacology (Berl). 2012 Feb;219(4):1153-64
pubmed: 21863234
J Clin Psychopharmacol. 2006 Jun;26(3):290-302
pubmed: 16702894
J Pharmacol Exp Ther. 2008 Apr;325(1):293-301
pubmed: 18198344
J Neurochem. 2012 Dec;123(6):932-43
pubmed: 22906103
Nat Med. 2010 Sep;16(9):1024-8
pubmed: 20729865
Endocrinology. 1998 Oct;139(10):4252-63
pubmed: 9751507
J Neurochem. 2001 Oct;79(1):221-4
pubmed: 11595774
Life Sci. 2001 Aug 10;69(12):1407-17
pubmed: 11531164
Biochem Pharmacol. 2003 Sep 15;66(6):965-76
pubmed: 12963483
Pharmacol Rev. 2015;67(1):176-97
pubmed: 25505168
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1675-9
pubmed: 9050837
Trends Pharmacol Sci. 1991 Jun;12(6):232-6
pubmed: 2048219

Auteurs

Miquel Martin (M)

Integrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute (IMIM), Parc de Recerca Biomedica de Barcelona (PRBB), C/Dr. Aiguader 88, 08003, Barcelona, Spain.
Laboratory of Neuropharmacology, Parc de Recerca Biomedica de Barcelona (PRBB), Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003, Barcelona, Spain.

Miriam Gutiérrez-Martos (M)

Laboratory of Neuropharmacology, Parc de Recerca Biomedica de Barcelona (PRBB), Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003, Barcelona, Spain.

Roberto Cabrera (R)

Laboratory of Neuropharmacology, Parc de Recerca Biomedica de Barcelona (PRBB), Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003, Barcelona, Spain.

Klaus Langohr (K)

Integrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute (IMIM), Parc de Recerca Biomedica de Barcelona (PRBB), C/Dr. Aiguader 88, 08003, Barcelona, Spain.
Department of Statistics and Operations Research, Universitat Politècnica de Cataluña (UPC)/BarcelonaTech, Jordi Girona 1-3, 08034, Barcelona, Spain.

Rafael Maldonado (R)

Laboratory of Neuropharmacology, Parc de Recerca Biomedica de Barcelona (PRBB), Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003, Barcelona, Spain.
Universitat Pompeu Fabra (CEXS-UPF), C/Dr. Aiguader 88, 08003, Barcelona, Spain.

Magi Farre (M)

Integrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute (IMIM), Parc de Recerca Biomedica de Barcelona (PRBB), C/Dr. Aiguader 88, 08003, Barcelona, Spain.
Universitat Autònoma de Barcelona (UDIMAS-UAB), C/Dr. Aiguader 88, 08003, Barcelona, Spain.
Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (IGTP), Carretera de Canyet s/n, 08916, Badalona, Spain.

Rafael de la Torre (R)

Integrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute (IMIM), Parc de Recerca Biomedica de Barcelona (PRBB), C/Dr. Aiguader 88, 08003, Barcelona, Spain. RTorre@imim.es.
Universitat Pompeu Fabra (CEXS-UPF), C/Dr. Aiguader 88, 08003, Barcelona, Spain. RTorre@imim.es.
CIBER Fisiopatologia de la Obesidad y la Nutrición (CIBERobn), Choupana s, /n 15706, Santiago de Compostela, Spain. RTorre@imim.es.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH